This expansion has been driven by the increasing interest in [18F]MK-6240 as a developmental and investigational tool in clinical trials.
In recent weeks, Cerveau has qualified production sites in Hayward, CA; Houston, TX; Phoenix, AZ; Birmingham, AL; as well as academic sites at John Hopkins University and Columbia University. These six (6) sites join an already existing network of ten (10) production sites in the US, Canada, Australia, and Belgium.
Twenty additional sites in Canada (1), the United States (3) Japan (4), Australia (4), Europe (4), and China (4) are undergoing capital expansion, technology transfer and start up processes. These sites will support a range of research and therapy clinical trial initiatives globally. This extensive production network will ultimately support imaging biomarkers licensed by Cerveau and its partners in research and development.
“Cerveau is focused on increasing access to the transformative technologies that we believe have the potential to advance brain health,” says Rick Hiatt, President and Chief Executive Officer, Cerveau Technologies, Inc. “This expansion of the biomarker production network underscores our commitment to the broader scientific research community and our support of industry’s initiatives to combat neurodegenerative disorders.”
About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180807005304/en/
Source: Cerveau Technologies, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20180807005304/en
